Pharma marketing that survives the compliance review.
The constraint in pharma is not creativity. It is what you are permitted to say, to whom, in which market. Work that ignores that gets pulled after launch, which costs more than building it correctly the first time.
What makes pharma marketing different from other healthcare marketing?
The binding limit is regulatory rather than creative. The same molecule may be promoted to prescribers in one country and not to patients at all in another, and the claims permitted differ by indication and by regulator. Material built without that in mind gets withdrawn after launch, and a withdrawal is far more expensive than the extra fortnight review would have taken up front. It also damages the standing of the medical affairs colleagues who have to defend it. The workable approach is to write to the constraint first and then make it good, rather than making it good and hoping the review passes. In practice that means claims mapped to approved language before any copy is drafted, a clear separation between disease awareness and product promotion, and adverse event reporting paths designed into any channel that permits a reply. Compliance belongs at the start as a design input, not at the end as a gate.
How this actually works.
HCP and patient handled separately
Two audiences with different permissible claims, different channels and different evidence thresholds. Collapsing them into one campaign is how brands get into trouble.
Every claim traced to a source
Substantiation is attached to the asset, so a reviewer can check it without a three week email chain.
Compliance in the brief, not the sign-off
Regulatory constraints are written into the creative brief. Reviewers stop being the department that says no and start being a checkpoint that passes.
Measured beyond impressions
Reach is the easy number. We instrument what happens after: script intent, HCP engagement depth, and where the funnel actually drops.
What people ask before buying this.
Which markets do you work in?
We build to the regulator you name. The framework is the same, the permissible claims are not, and we will not assume one market's rules apply in another.
Can you work with our MLR process?
Yes. The point of putting substantiation in the brief is to make MLR faster rather than to route around it.
This works hardest with the pieces around it.
Content marketing
Scattered posts do not compound; clusters do. Service, cost and comparison pages that…
Open →Layer 02Healthcare SEO
Ranking is not the goal. A page that ranks first for a term nobody books from is a vanity…
Open →Layer 02Medical tourism
An international patient is not a local enquiry with a longer address. The decision runs…
Open →Is this the piece you are missing?
Thirty minutes and rough numbers is enough for an honest read, including when the answer is that you do not need this.